KLRK1 and cancer: Therefore, the potential of NKG2D-based multispecific CAR-T therapies in B-cell malignancies might be improved by the patient’s pre-conditioning regimen, standard prior treatment lines (e.g. vincristine and doxorubicin) or by combining NKG2DL CAR T-cells with an anti-cancer treatment that increases NKG2DL expression on the surface of cancer cells (e.g. bortezomib and valproate).